Medicinal Chemistry of Anticancer Drugs
- 3rd Edition - April 28, 2023
- Latest edition
- Authors: Carmen Avendaño, J. Carlos Menéndez
- Language: English
This third edition of Medicinal Chemistry of Anticancer Drugs, provides an updated resource for students and researchers from the point of view of medicinal chemistry and drug desi… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
This third edition of Medicinal Chemistry of Anticancer Drugs, provides an updated resource for students and researchers from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents.
Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. This new edition includes updated sections on the hot topic of cancer immunotherapy, cancer polypharmacology, multitargeted cancer therapy, medicinal chemistry of cancer diagnosis, theranostic anticancer agents, and pre-mRNA processing in cancer. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a unique and valuable perspective from the point of view of medicinal chemistry and drug design. It will be useful to undergraduate and postgraduate students of medicinal chemistry, pharmacology, biological chemistry, pharmacy and other health sciences. Researchers and practitioners will find a comprehensive treatment of the topic and a large number of references to reviews and the primary literature.
Key features
Key features
- Provides a resource that is organized consistently based on targets and mechanisms of action from a molecular point-of-view
- Focuses on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents, providing a rationalization on the action of these type of drugs and the design of new active structures
- Features a large number of color figures which give information in a clear-and-concise way
- Includes extensive references to review articles and primary literature
- Includes updated sections on the hot topic of cancer immunotherapy, cancer polypharmacology, multitargeted cancer therapy, medicinal chemistry of cancer diagnosis, theragnostic anticancer agents, and pre-mRNA processing in cancer
Readership
Readership
The book is targeted at both students and medicinal chemists. Such a compendium of work is a fantastic source of information. The topics covered also will be of interest to a wide variety of people, from specialists to people with general interest in the area.
The audience for the project will likely be medicinal chemists both from industry and academia. Regarding the academic qualification, principal investigators as well as graduate students working on anticancer agents will be interested in the publication.
The audience for the project will likely be medicinal chemists both from industry and academia. Regarding the academic qualification, principal investigators as well as graduate students working on anticancer agents will be interested in the publication.
Table of contents
Table of contents
1. Introduction
2. Antimetabolites
3. Anticancer Drugs That Modulate Hormone Action
4. Anticancer strategies involving radical species
5. DNA Alkylating Agents
6. Anticancer Drugs That Interact with the DNA Minor Groove
7. Anticancer Drugs acting by DNA intercalation and topoisomerase inhibition
8. Epigenetic Therapy of Cancer
9. Anticancer Drugs Targeting Tubulin and Microtubules
10. Drugs Tacting on signaling pathways, part 1: Tirosine kinase inhibitors
11. Anticancer drugs acting on signaling pathways, part 2
12. Protein degradation-based cancer therapy
13. Cancer immunotherapy
14. Miscellaneous small-molecule and biological approaches to cancer therapy
15. Drug Targeting in Anticancer Chemotherapy
16. Drugs That Modulate Resistance to Anticancer Agents
17. Cancer Chemoprevention
2. Antimetabolites
3. Anticancer Drugs That Modulate Hormone Action
4. Anticancer strategies involving radical species
5. DNA Alkylating Agents
6. Anticancer Drugs That Interact with the DNA Minor Groove
7. Anticancer Drugs acting by DNA intercalation and topoisomerase inhibition
8. Epigenetic Therapy of Cancer
9. Anticancer Drugs Targeting Tubulin and Microtubules
10. Drugs Tacting on signaling pathways, part 1: Tirosine kinase inhibitors
11. Anticancer drugs acting on signaling pathways, part 2
12. Protein degradation-based cancer therapy
13. Cancer immunotherapy
14. Miscellaneous small-molecule and biological approaches to cancer therapy
15. Drug Targeting in Anticancer Chemotherapy
16. Drugs That Modulate Resistance to Anticancer Agents
17. Cancer Chemoprevention
Product details
Product details
- Edition: 3
- Latest edition
- Published: April 28, 2023
- Language: English
About the authors
About the authors
CA
Carmen Avendaño
Mª del Carmen Avendaño López received her doctoral degree in Pharmacy at the Complutense University of Madrid (UCM) in 1970. In 1986, she became Full Professor of Organic Chemistry at the Department of Organic and Pharmaceutical Chemistry of this university, being responsible for one of its research groups. Between 1993 and 2009, she was a member of the Scientific Advising Committee for the Profarma Program, organized by the Spanish Ministry for Industry to incentivize research activities at the pharmaceutical industry. She was appointed Vice-rector in charge of Postgraduate Degrees at the International University “Menéndez y Pelayo” in 2005-2007. She participated in the development of the Spanish Society for Therapeutical Chemistry and has also been a member of several scientific international societies and assessment committees. Since 1999, she is a Fellow of the Spanish National Royal Academy of Pharmacy where she is in charge of all activities related to Medicinal Chemistry, with particular focus on the relevance of chemistry in drug discovery and development. She has co-authored several chapters in periodical series and encyclopedias, including “Comprehensive Heterocyclic Chemistry” and “Science of Synthesis”, and has edited and co-authored several Medicinal Chemistry textbooks, most notably “Introducción a la Química Farmacéutica”, published by McGraw-Hill Interamericana in 1993 and 2001. In 2008, she co-authored with Dr. Menéndez the first edition of “Medicinal Chemistry of Anticancer Drugs“ for Elsevier. Her research activities, documented in about 200 publications and some patents in collaboration with the pharmaceutical industry, have dealt with the development of synthetic methodologies to obtain biologically active molecules, with particular focus on antitumor natural compounds.
Affiliations and expertise
Organic and Medicinal Chemistry Unit, Faculty of Pharmacy, Complutense University, Madrid, SpainJM
J. Carlos Menéndez
José Carlos Menéndez was born in Madrid (1960) and obtained degrees in Pharmacy from Universidad Complutense at Madrid, UCM (1982, with Excellence Award) and Chemistry from UNED (1985) followed by a Ph.D. in Pharmacy from UCM in 1988, under the supervision of Dr. Mónica M. Söllhuber, with Excellence Award. In August 1988, he joined the group of Professor Steven V. Ley at Imperial College, London, where he worked on the total synthesis of the natural ionophoric antibiotic routiennocin. In September 1989, he returned as a Profesor Titular to the Organic and Medicinal Chemistry Department at UCM, where he has pursued his teaching and research career ever since, having obtained Accreditation as a Full Professor in 2010. He has varied research interests, related, on one hand, to medicinal chemistry work in the fields of neurodegeneration (prion disease, Alzheimer’s disease, ischemic injury) and chemotherapy (cancer, tuberculosis, leishmaniasis). Other projects pursued in his group are focused on the development of new synthetic methodology, including work on microwave-assisted organic synthesis, CAN as a catalyst for organic synthesis, green chemistry and the development new domino and multicomponent reactions for the preparation of biologically relevant bicyclic systems and nitrogen heterocycles. This work has been documented in about 210 research papers, reviews and chapters and 9 patents. Additionally, he has co-authored two textbooks in Medicinal Chemistry for McGraw-Hill Interamericana (?Introducción a la Química Farmacéutica, 2nd Ed." 2001 and "Ejercicios de Química Farmacéutica", 1997), and a third one for Elsevier ("Medicinal Chemistry of Anticancer Drugs", 2008). He is the coordinator of a Master Course on Drug Discovery, and the coordinator at UCM of a Ph.D. program in Medicinal Chemistry. He has collaborated with many research groups in UK, Italy, France, and India and also has some long-standing collaborations with several chemical and pharmaceutical Spanish companies. He has been the head of the Organic Microanalysis service at UCM since its creation in 1991. Since 2004, he is a Corresponding Member of the Spanish Royal Academy of Pharmacy. He has been a Visiting Professor at Université Paul Cézanne (Aix-Marseille III, France) in 2007 and at the Istituto di Studi Avanzati (ISA), Bologna University, Italy, in 2014.
Affiliations and expertise
Organic and Medicinal Chemistry Unit, Faculty of Pharmacy, Complutense University, Madrid, SpainView book on ScienceDirect
View book on ScienceDirect
Read Medicinal Chemistry of Anticancer Drugs on ScienceDirect